Placental F4-Neuroprostanes and F2-Isoprostanes are altered in gestational diabetes mellitus and maternal obesity
Résumé
We investigated whether gestational diabetes mellitus (GDM) associated with maternal obesity modifies the
placental profile of F4-Neuroprostanes and F2-Isoprostanes, metabolites of non-enzymatic oxidation of docosahexaenoic
acid (DHA) and arachidonic acid (AA), respectively. Twenty-five placental samples were divided into
lean (n=11), obesity (n=7) and overweight/obesity+GDM (n=7) groups. F4-Neuroprostanes and F2-Isoprostanes
were higher in obesity compared to lean controls, but reduced to levels similar to lean women when obesity is
further complicated with GDM. Lower content of F2-Isoprostanes suggests adaptive placental responses in GDM
attenuating oxidative stress. However, low levels of placental F4-Neuroprostanes may indicate impaired DHA
metabolism in GDM, affecting fetal development and offspring health. These results were not related to differences
in placental content of DHA, AA and polyunsaturated fatty acids status nor to maternal diet or gestational
weight gain. Placental DHA and AA metabolism differs in obesity and GDM, highlighting the importance of
investigating the signalling roles of F4-Neuroprostanes and F2-Isoprostanes in the human term placenta.